News

ABCT, the Accelerator for Biosciences in Connecticut, is open to research scientists, engineers, MD's, MBA's faculty, graduate students, post docs, and technologists based in Connecticut who meet certain eligibility requirements. The deadline to apply for the 2019 cohort is October 23 at 5:00 pm. Information session will be held Sept 13 at 4:30 pm at The Commons in Groton, and Sept 18 at 12 noon at UConn TIP. Details of the program RSVP for 9/13 information session RSVP for 9/18 information session ABCT 2018-2019 Application Form

UConn Health’s Dr. Mayu Inaba, an assistant professor in the Department of Cell Biology, has received nearly $2 million from the National Institutes of Health National Institute of General Medical Sciences to conduct a study of the molecular and cellular mechanisms that regulate asymmetric stem cell division. During her postdoctoral research, Inaba discovered microtube-based nanotubes, which are microscopic protrusions found only on stem cells and not on other differentiated cells produced from the same parent cell. This led her to hypothesize that these structures are responsible for directing asymmetrical division. These tubes are also probably responsible for receiving and interpreting [...]

A Wallingford company that makes epinephrine auto-injectors for people with potentially life-threatening allergies is making news. Summit Street Medical had Connecticut's largest venture-capital deal during the first quarter of this year, at $1.9 million more

Marna P. Borgstrom, chief executive officer of Yale New Haven Hospital and Yale New Haven Health, is one of seven healthcare executives elected to the American Hospital Association (AHA) Board of Trustees for a three-year term. Marna Borgstrom has served as the chief executive officer of Yale New Haven Hospital and Yale New Haven Health since 2005. With revenues of $4.5B, Yale New Haven Health is the largest health system in the region and largest employer in Connecticut. more

Pine Lake Laboratories is a GLP and GMP compliant analytical and bioanalytical contract research organization located in Bristol, CT.  It features a state of the art laboratory with dedicated scientists committed to delivering efficient and innovative solutions for even the most challenging projects. more

Biohaven has enrolled the first patient in a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator for the treatment of mild-to-moderate Alzheimer’s disease (AD). Howard Feldman, MD, FRCP, Director of the ADCS and Professor of Neurosciences at University of California San Diego School of Medicine added, “We are excited that the first patient has been enrolled into this innovative clinical trial that we are conducting with Biohaven. The preclinical evidence for the active metabolite of trigriluzole to modulate glutamate and confer neuroprotective effects in patients with AD is compelling, and the new formulation of trigriluzole should improve [...]

Boehringer Ingelheim has secured the option to license a cystic fibrosis gene therapy. The agreement will see Boehringer work with British academics and Oxford BioMedica (OXB) to develop an inhaled, lentiviral vector-based gene therapy treatment for cystic fibrosis. The U.K. Cystic Fibrosis Gene Therapy Consortium (GTC), one member of the collaboration, laid the groundwork for the deal 17 years ago when it began exploring the viability of treating cystic fibrosis with a gene therapy. Since then, the academic partners from Edinburgh, London, and Oxford that make up the GTC have taken a lentiviral vector gene therapy to the cusp of [...]

Melinta Therapeutics reports that the Centers for Medicare & Medicaid Services has granted a new technology add-on payment (NTAP) for Vabomere™ (meropenem and vaborbactam) when administered in the hospital inpatient setting. “We are pleased with [this] decision to grant NTAP designation to Vabomere, which underscores our belief that Vabomere represents a significant new advancement in addressing the increasing incidence of KPC-producing Enterobacteriaceae, for which there are currently limited treatment options,” said Dan Wechsler, President and CEO of Melinta. more

BioCT congratulates the Women In Bio Boardroom Ready class of 2018. We are especially proud of BioCT member Mary Kay Fenton, EVP and CFO of Achillion, for being accepted into the Boardroom Ready program. Dawn Dawn Hocevar President & CEO BioCT more

Based in Stamford, Richard Imbruce has begun selling the Rapid Oxygen R15 device, which is designed to provide a critical flow of oxygen for people suffering stroke or other crises in which every minute of oxygen counts in warding off brain damage. Imbruce envisions the system being installed alongside defibrillators to provide tandem tools to help those providing first aid. more